Dublin, Ireland, November 19th 2018 – DS Biopharma (DS), a privately held clinical stage biopharmaceutical company specialising in the development of novel bioactive lipids, today announced the grant of a United States (US) patent protecting the use of DS107 for the treatment of atopic dermatitis (AD).
The US Patent and Trademark Office (USPTO) has issued patent No. 10,105,333 entitled “Pharmaceutical Compositions Comprising DGLA and Use of Same” covering the use of oral DS107 as a treatment for AD. The previously granted US patent No. 9,682,055 along with this additional patent, provide exclusivity to DS107 for all oral compositions and methods of use in AD until 2034.
Mr. Tien Nghiem, Director of Product Development and Intellectual Property at DS Biopharma, commented: “This patent grant is another important milestone for the Company and significantly strengthens the exclusivity protection of DS107. DS Biopharma continues to prosecute other DS107 patent families in the US and other key jurisdictions.”
About DS Biopharma
DS Biopharma (DS), headquartered in Dublin, Ireland, is a privately held, clinical stage, pharmaceutical drug discovery and development company, which develops new medicines for unmet needs in dermatological diseases. The compounds under development are based on a novel bioactive lipid platform. These lipid molecules have been shown to be crucial to the pathways of several conditions including skin disorders such as atopic dermatitis (AD). The Company’s lead compound; DS107 is being explored clinically as both a topical cream for mild to moderate AD (phase 3 ready) and separately as an oral capsule in moderate to severe AD (phase 2b). DS holds multiple patents and pending applications protecting the DS107 product and its clinical uses.
Contact DS Biopharma: email@example.com, 0035312933590